Evaluation of the Effectiveness of Riamilovir in Prevention of COVID-19: Mathematical Simulation Results

   Aim. Evaluation of the effectiveness of the preventive use of the directacting antiviral drug riamilovir in reducing the incidence of COVID-19, as well as its impact on the dynamics of infection spread using mathematical simulation on the example of the Kurgan region population to optimize preventive strategies for epidemiologically significant diseases.

   Material and methods. To simulate the spread of COVID-19 in the Kurgan region, the extended SEIR model was used, taking into account the effect of riamilovir on the likelihood of contracting a new coronavirus infection. The numerical solution of the system of differential equations was carried out using the 4^th order Runge-Kutta method. The input parameters of the model
were based on demographic data from the region and the results of a clinical study of riamilovir preventive efficacy against COVID-19 and acute respiratory viral infections. The scenarios under consideration involve 30 % and 50 % of the population taking the drug, which reduced the likelihood of infection by 25.7 % and 40 %, respectively.

   Results. Based on mathematical simulation, it has been established that the preventive use of riamilovir by 30% or 50% of the population shifts the peak of the epidemic to a later date, and the maximum number of active cases is significantly reduced compared to the scenario without the drug. The total number of cases is decreasing, which reduces the burden on the healthcare system and improves control over the spread of infection.

   Conclusion. Mathematical simulation has shown that the scenario of preventive use of riamilovir on the example of the Kurgan region can significantly reduce the incidence of infections with epidemic potential, reduce the burden on the healthcare system, and slow down the peak of the epidemic.

1. Sabitov A. U., Sorokin P. V., Dashutina S.Yu. The efficacy and safety of Riamilovir in the treatment of patients with COVID-19. Antibiotiki i Khimioter. 2021; 66: 1–2: 33–37. doi: 10.24411/0235-2990-2021-66-1–2-33-37. (in Russian)

2. Maltsev O. V., Kozlov K. V., Lvov N. I., Sukachev V. S., Saulevich A. V., Karyakin S. S., Sharabkhanov V. V., Dambaev I. S. The experience of using the nucleoside analogue of riamilovir in the treatment and prevention of acute respiratory viral infections in young people. In the collection: Unresolved issues of etiotropic therapy of topical infections. Proceedings of the All-Russian Annual Scientific and Practical Conference. Saint Petersburg, 2024; 155–162. (in Russian)

3. Report on the work done by the Consolidated Medical Detachment of the Ministry of Defense of the Russian Federation during its work in the Kurgan region. St. Petersburg, 2021. (in Russian)

4. Alimova M. M., Bochkova V. N. Psychological health of medical personnel under stressful working conditions amid the COVID-19 pandemic. Academic Journal of West Siberia = Akademicheskij Zhurnal Zapadnoj Sibiri. 2021; 17 (1–90): 25–26. (in Russian)

5. Boyko O. M., Medvedeva T. I., Enikolopov S. N., Vorontsova O. Yu. Compliance to epidemiological safety norms and interpretation of events during the COVID-19 pandemic. Deviant Behavior (Russia). 2020; 4 (2): 8–21. doi: 10.32878/devi.20-4-02(7)-8-21. (in Russian/in English)

6. Order of the Ministry of Health of the Russian Federation No. 677n dated December 12, 2023 «On Amendments to Order of the Ministry of Health of the Russian Federation No. 1122n dated December 6, 2021 «On Approval of the National calendar of Preventive Vaccinations, the calendar of preventive Vaccinations for epidemic indications and the Procedure for preventive Vaccinations». The link is active on 02/23/2025] [http://publication.pravo.gov.ru/Document/view/0001202112200070. (in Russian)

7. Current data on the number of reported COVID-19 cases in Russia [archive]. The link is active on 02/23/2025. https://xn-90aivcdt6dxbc.xn-p1ai/stopkoronavirus. (in Russian)

8. Kritsky I. S., Zurochka V. A., Hu D., Sarapultsev A. P. Assessment of the dynamics of changes in the number of seropositive patients with antibodies against SARS-CoV-2 during the two and a half years of the COVID-19 pandemic. Russian Journal of Immunology. 2022; 25 (2): 219–226. doi: 10.46235/1028-7221-1153-DOC. (in Russian)

9. Ministry of Health of the Russian Federation. Interim guidelines «Prevention, diagnosis and treatment of novel coronavirus infection (COVID-19)». Version 18 dated October 26, 2023 The link is active on 02/23/2025] . (in Russian)

10. Yatsyshina S. B., Artamonova A. A., Yelkina M. A., Valdokhina A. V., Bulanenko V. P., Berseneva A. A., Akimkin V. G. Genetic characteristics of influenza A and B viruses circulating in Russia in 2019–2023. Journal of Microbiology, Epidemiology and Immunobiology. 2024; 101 (6): 719–734. (in Russian)

11. Charness M. E., Gupta K., Stack G. et al. Emerging S. A.RS-CoV-2 Resistance After Antiviral Treatment. JAMA Network Open. 2024; 7 (2): e2824050. Accessed February 23, 2025.

12. Iketani S., Liu L., Guo Y. et al. Transmissible S. A.RS-CoV-2 Variants with Resistance to Clinical Protease Inhibitors. Science Advances. 2023; 9 (31): eade8778. Accessed February 23, 2025.

13. Zhou Y., Gammeltoft K. A., Ryberg L. A. et al. Emergence of Transmissible S. A.RS-CoV-2 Variants with Decreased Sensitivity to Nirmatrelvir. Nature Communications. 2024; 15 (1): 51924. Accessed February 23, 2025.

14. Sbartsalya V. A., Gladkikh A. S., Milichkina D. M., Bachevskaya A. V., Popova M. R., Sharova A. A., Cherepanova E. A., Dedkov V. G., Totolyan A. A. The structure of acute respiratory viral infections in the Northwestern Federal District during the COVID-19 pandemic (2021-2022). Infection and immunity. 2024; 14 (5): 917–926.] https://iimmun.ru/iimm/article/view/17644. Ssylka aktivna na 23. 02. 2025.

15. Ryoo S., Koh D. H., Yu S.Y. et al. Clinical efficacy and safety of interferon (Type I and Type III) therapy in patients with COVID-19 : A systematic review and meta-analysis of randomized controlled trials. PLoS One. 2023; 18 (3): e0272826. doi: 10.1371/journal.pone.0272826.

16. Wittling M. C., Cahalan S. R., Levenson E. A., Rabin R. L. Shared and unique features of human Interferon-beta and Interferon-alpha subtypes. Front Immunol. 2020; 11: 605673. doi: 10.3389/fimmu.2020.605673.

17. Kasianenko K. V., Lvov N. I., Maltsev O. V., Zhdanov K. V. Nucleoside analogues for the treatment of influenza: history and experience. Journal Infectology. 2019; 11 (3): 20–26. doi: 10.22625/2072-6732-2019-11-3-20-26. (in Russian)

18. Sabitov A. U., Sorokin P. V., Dashutina S. Yu. Experience of the preventive use of the drug Riamilovir in the foci of coronavirus infection (COVID-19). Terapevticheskii Arkhiv (Ter. Arkh.). 2021; 93 (4): 435–439. doi: 10.26442/00403660.2021.04.200751. (in Russian)

19. Sabitov A. U., Lioznov D. A., Zhdanov K. V., Tihonova E. P., Esaulenko E. V., Sorokin P. V. Results of a randomized double-blind multicenter clinical trial of the efficacy and safety of the drug riamilovir for the prevention of COVID-19. Terapevticheskii Arkhiv (Ter. Arkh). 2024; 96 (3): 280–285. doi: 10.26442/00403660.2024.03.202652. (in Russian)

20. Kozlov K. V., Maltsev O. V., Kasyanenko K. V., Sukachev V. S., Saulevich A. V., Karyakin S. S., Dubrovin A. D., Smirnov R. N. Effectiveness of riamilovir in preventing respiratory viral infection among young people from organized collectives. Terapevticheskii Arkhiv. 2024; 96 (11): 1035–1041. doi: 10.26442/00403660.2024.11.203024. (in Russian)

21. Kim P. S., Read S. W., Fauci A. S. Therapeutic strategies to address COVID-19: Repurposing and the need for combination therapies. Science Translational Medicine. 2020. doi: 10.1126/scitranslmed.abc8965. Accessed February 23, 2025.